Skip to main content
. Author manuscript; available in PMC: 2017 Jun 4.
Published in final edited form as: Lancet. 2016 Mar 24;387(10035):2312–2322. doi: 10.1016/S0140-6736(15)01316-1

Table 2.

Blind prediction performance of the TB risk signature on the ACS test set by RNA-Seq and qRT-PCR, and on the GC6-74 cohorts from South Africa and The Gambia by qRT-PCR.

Prediction accuracy (95% CI)

Cohort Platform Days
before
TB
ROC AUC (95%
CI)
ROC p-
value
Sensitivity Specificity Threshold
ACS Test
  All ACS
  Test
RNA-Seq 0·686 (0·523,
0·849)
0·018 41·7% (22·3%,
64·5%)
89·9% (82·6%,
94·0%)
82%
  All ACS
  Test
qRT-PCR 0·693 (0·536,
0·850)
0·0095 46·7% (27·8%,
66·6%)
90·9% (83·8%,
94·7%)
76%

GC6-74
  All GC6-
  74
qRT-PCR 1–720 0·694 (0·625,
0·763)
<0·0001 48·8% (39·9%,
57·7%)
82·8% (78·7%,
86%)
76%
  South
  Africa
qRT-PCR 1–720 0·720 (0·633,
0·806)
<0·0001 43·2% (31·7%,
55·5%)
87·7% (82·7%,
91·2%)
79%
  The
  Gambia
qRT-PCR 1–720 0·665 (0·555,
0·775)
0·001 50% (37·1%,
62·8%)
81·9% (75·5%,
86·7%)
78%
  All GC6-
  74
qRT-PCR 1–360 0·718 (0·637,
0·800)
<0·0001 53·7% (42·6%,
64·3%)
82·8% (78·7%,
86%)
76%
  All GC6-
  74
qRT-PCR 361–720 0·648 (0·532,
0·764)
0·0048 39·3% (25·8%,
54·8%)
85·5% (81·7%,
88·5%)
79%